{
  "docId": "019dd923-5f69-752d-a9b6-0d0782a66fef",
  "docSlug": "GU7tHQNbAVEJiBcjPEiK",
  "documentTitle": "See the pitch deck that Compass Pathways used to raise $80 million and fuel its rise into one of the world's biggest psychedelics companies",
  "authorId": "Pitchdecks",
  "authorName": "Compass Pathways",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.333,
  "pageNumber": 18,
  "pageCount": 28,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "peer_benchmark",
  "function": "cite_precedent",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": "The slide uses a case study format to illustrate the impact of clinical milestones on valuation.",
  "elementsJson": [
    "action_title",
    "bullet_list",
    "line_chart",
    "callout_box",
    "footnote"
  ],
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5f69-752d-a9b6-0d0782a66fef/18",
  "deckHref": "/decks/019dd923-5f69-752d-a9b6-0d0782a66fef",
  "deckJsonHref": "/decks/019dd923-5f69-752d-a9b6-0d0782a66fef.json",
  "deckAnchorHref": "/decks/019dd923-5f69-752d-a9b6-0d0782a66fef#slide-18",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Market cap of $5.5bn (09-Jan-2018) driven by positive Phase II and III results",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd952-9d69-7444-a587-80e7b053f502",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.75,
        "x": 0.2,
        "y": 0.48
      },
      "kind": "chart",
      "text": "Market cap of $5.5bn (09-Jan-2018) driven by positive Phase II and III results. Significant share price and valuation uplift post successful results Phase II (+£1.7b) and Phase III (+£1.6b)",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8bf1c403-825b-447f-9cb3-44ff75dbf7be",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.75,
        "x": 0.2,
        "y": 0.14
      },
      "kind": "list",
      "text": "KEY ASSETS: Relevant assets in same indication (MDD, PPD, Bipolar Depression). SAGE-547 (registration phase): IV formulation being investigated for Post-Partum Depression (PPD), as well as epilepsy. SAGE-217 (Phase III): oral drug being investigated for among others Major Depressive Disorder (MDD), PPD, and Bipolar Depression",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "413e7f9b-4a59-4548-b401-4514bfa8db63",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.75,
        "x": 0.2,
        "y": 0.78
      },
      "kind": "list",
      "text": "CONSTRAINTS: Despite positive vote FDA advisory committee on risk/benefit profile SAGE-547 (Nov-2018), potential strict requirements may limit future uptake. 72-hour infusion process to be done under 24/7 medical care. FDA panel vague on additional data required for home infusion",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8d7a5bcd-f568-47bb-b471-9a1ac66f4001",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.75,
        "x": 0.2,
        "y": 0.32
      },
      "kind": "list",
      "text": "CLINICAL DEVELOPMENT: SAGE-217 positive Phase III results in PPD (Jan 2019). PPD Phase III met primary and secondary endpoints (Jan-2019). MDD Phase II met primary endpoint (Dec 2017). PPD Phase II met primary endpoint (Jun 2017)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9b2831ac-eb9a-4ce0-b010-298fd67a8218",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Market cap: £5.5bn",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd952-9d69-7444-a587-8755742a4c28",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.45,
        "x": 0.05,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: ClinicalTrials.gov; Comparables Analysis; SAGE website; Bloomberg Biomedtracker (2016); Endpoints News (2018); Oanda.com",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4ff9dac0-a883-427d-aa5d-2496b896725e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.03
      },
      "kind": "title",
      "text": "Sage Therapeutics: Significant valuation uplift post successful Phase II (+£1.7b) and Phase III (+£1.6b) results",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "72a38cfd-1a0a-48af-8145-19b939e6453a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Slide recipe: the peer-gap chart",
      "slug": "peer-gap-chart-recipe",
      "agent": "designer",
      "layer": "slide",
      "matchId": "0fc95c23-7661-4afa-8d08-a18168f8a21d",
      "evidence": "Significant share price and valuation uplift post successful results Phase II (+£1.7b) and Phase III (+£1.6b)",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "case-study",
      "slug": null,
      "matchId": "1c5783ad-d062-4d48-b384-05ad48582b51",
      "evidence": "The slide presents a specific company (Sage Therapeutics) as a precedent for valuation uplift based on clinical milestones.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 28,
      "from": 12,
      "beatId": "f8bdb5f2-d1dc-4c32-98a9-d6926ec9a7dc",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Impact & Next Steps",
      "beatSlug": "consultants-gambit-impact-next-steps",
      "evidence": "Slides 12-28 outline the development program, timeline, and team, showing a clear plan for implementation.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}